Skip to main content
. 2015 May 13;114(1):585–607. doi: 10.1152/jn.00012.2015

Fig. 8.

Fig. 8.

Intragastric D1 dopamine receptor (D1R) antagonist SCH-23390 (SCH1.5) and D2R antagonist raclopride (RAC0.5) attenuate DEP20’s effect on weight loss, food intake, locomotion, and stereotypic head movements. A: the change in body weight during 7 days of treatment with daily intragastric infusions of Sal (○), RAC0.5 (□), SCH1.5 (◇), DEP20 (▲), DEP20+RAC0.5 (■), and DEP20+SCH1.5 (⧫) starting on day 1 and terminating on day 7 (gray shading). The weight loss produced by DEP20 was reduced in the presence of either RAC0.5 or SCH 1.5. Note that neither D2 (□) nor D1 (◇) antagonists alone induced weight loss. B: graph showing the change in 24-h food intake under the same conditions as in A. Infusion of DEP20+RAC0.5 or DEP20+SCH1.5 increased food intake compared with DEP20 alone. C: effect of these DA antagonists on locomotion in the same subjects and grouping as in A measured in an open-field arena. All groups displayed a gradual decay in exploratory activity within 20 min from introduction to the open field (BL). Intragastric infusions were then made at 30-min intervals with saline, at 60 min with DEP20, and at 90 min with and/or without RAC0.5 or SCH1.5. Compared with DEP20 alone, repeated administrations of DEP20+RAC0.5 or DEP20+SCH1.5 decreased the magnitude and delayed the onset of locomotion. D: graph showing the reduction in the stereotypy induced by DEP20+RAC0.5 or DEP20+SCH1.5.